Instrument Inactif

Communiqués Plasmatech Biopharmaceuticals Inc Nasdaq

Actions

US72754H1095

Produits pharmaceutiques

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

12/06	Abeona Therapeutics Inc. annonce la démission de Michael Amoroso de son poste de membre du conseil d'administration et du comité de nomination et de gouvernance d'entreprise, avec effet au 11 juin 2026	CI
04/06	Abeona Therapeutics Inc participe à une réunion de pré-IND avec la FDA concernant l'ABO-701	CI

Communiqués

01/06	Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
26/05	Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences	AQ
13/05	Abeona Therapeutics : Presentation Q1 2026 PDF Q1 2026	PU
13/05	Abeona Therapeutics: Q1 Earnings Snapshot	AQ
13/05	Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update	AQ
11/05	Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®	AQ
04/05	Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
04/05	Abeona Therapeutics® Announces Date of First Quarter Financial Results	AQ
01/05	Abeona Therapeutics : reg; Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	PU
07/04	Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors	AQ
06/04	Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
02/04	Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York	AQ
17/03	Abeona Therapeutics: Q4 Earnings Snapshot	AQ
17/03	Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates	AQ
09/03	Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch	AQ
04/03	Abeona Therapeutics Announces Date of Fourth Quarter, Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference	AQ
03/03	Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference	AQ
09/02	Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
31/12	Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
15/12	Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer	AQ
11/12	Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas	AQ
08/12	Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy	AQ
01/12	Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
13/11	Abeona Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates	AQ
12/11	Abeona Therapeutics: Q3 Earnings Snapshot	AQ